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When using an analytical method, defining an Analytical Target Profile (ATP) focused on 21 
quantitative performance represents a key input, and this will drive the method development 22 
process. In this context, two case studies were selected in order to demonstrate the potential of 23 
a Quality-by-Design (QbD) strategy when applied to two specific phases of the method 24 
lifecycle: the pre-validation study and the validation step. The first case study focused on the 25 
improvement of a Liquid Chromatography (LC) coupled to Mass Spectrometry (MS) 26 
stability-indicating method by the means of the QbD concept. The Design of Experiments 27 
(DoE) conducted during the optimization step (i.e. determination of the qualitative Design 28 
Space (DS)) was performed a posteriori. Additional experiments were performed in order to 29 
simultaneously conduct the pre-validation study to assist in defining the DoE to be conducted 30 
during the formal validation step. This predicted protocol was compared to the one used 31 
during the formal validation. A second case study based on the LC/MS-MS determination of 32 
glucosamine and galactosamine in human plasma was considered in order to illustrate an 33 
innovative strategy allowing the QbD methodology to be incorporated during the validation 34 
phase. An operational space, defined by the qualitative DS, was considered during the 35 
validation process rather than a specific set of working conditions as conventionally 36 
performed. Results of all the validation parameters conventionally studied were compared to 37 
those obtained with this innovative approach for glucosamine and galactosamine. Using this 38 
strategy, qualitative and quantitative information were obtained. Consequently, an analyst 39 
using this approach would be able to select with great confidence several working conditions 40 
within the operational space rather than a given condition for the routine use of the method. 41 
This innovative strategy combines both a learning process and a thorough assessment of the 42 
risk involved. 43 
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1 Introduction 48 
Numerous reference documents such as the International Conference on Harmonisation (ICH) 49 
guidelines [1-4] and the U.S. Pharmacopeia (USP) recommendations [5-7] deal with the 50 
method development process and the topic of validation. All of these documents emphasize 51 
the need to manage risk during the entire method lifecycle. As already widely discussed in the 52 
scientific literature [8-13], applying the Quality-by-Design (QbD) concept to analytical 53 
methods ensures a controlled risk-based development of a method where quality assurance 54 
will be guaranteed [1]. Nowadays, the QbD concept is mainly applied to the development step 55 
of the method as an alternative approach to the Quality-by-Testing methodology, as discussed 56 
by Hubert et al. [14]. However, the QbD strategy encompasses more than this single step of 57 
the method lifecycle. For instance, the control strategy forms part of this strategy, since this is 58 
recommended to ensure optimal method performance [4], although the robustness of the 59 
method is assessed separately by the determination of the analytical method Design Space 60 
(DS). This control strategy needs to be implemented in order to consolidate the understanding 61 
of the method and to allow its continuous improvement [15]. In the same way, the validation 62 
step must be part of the continuous evaluation of the analytical method rather than being an 63 
isolated activity. A similar approach is recommended by the FDA for process validation, and 64 
this has been illustrated by Katz [16] et al. 65 
In this context, defining the objectives of the method by means of an Analytical Target Profile 66 
(ATP) [17] is the major first step of the QbD methodology. As established by a stimuli article 67 
of the USP Statistics Expert Committee [18], an ATP for an analytical procedure may be 68 
defined, for example, as follows: “The procedure should be able to quantify [analytes] in the 69 
presence of [X, Y, Z] over a range of A% to B% of the nominal concentration with an 70 
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accuracy and uncertainty ensuring the reportable results fall within +/-C% of the true value 71 
with quantified guarantees”. Taking this definition into account, it therefore seems essential 72 
that the ATP be established before starting to develop the procedure. This ensures the 73 
definition in advance of the required level of performance given the user requirements. 74 
Consequently, the ATP should remain the reference concept throughout the method lifecycle. 75 
The goals of the present study are set within this context. The capability of the procedure to 76 
meet the specifications needs to be continuously reconsidered throughout the method 77 
lifecycle. As a first stage towards a full integration of the optimization and validation phases, 78 
the power of the QbD step using the Design of Experiments (DoE) was enhanced by 79 
performing additional experiments in order to obtain quantitative data leading to the gathering 80 
of valuable pre-validation information. In order to illustrate the feasibility of this innovative 81 
approach, a case study already presented elsewhere [14] is selected. This research was 82 
centered on the optimization of a Liquid Chromatography (LC) coupled to Mass Spectrometry 83 
(MS) stability-indicating method using a QbD methodology. The study was undertaken in 84 
order to identify the operational conditions, i.e. the Design Space (DS), that would ensure 85 
good results in the future in terms of the separation of the two analytes as well as protection 86 
from interfering peaks caused by the presence of impurities and/or co-extracted 87 
pharmaceutical matrix compounds. Using an a posteriori study, conducted as part of the DoE 88 
implemented during the QbD optimization step, the demonstration is made that this particular 89 
step of the method lifecycle could also be used to estimate the calibration model, the 90 
accuracy, and the limits of detection/quantification, as well as assisting in defining the DoE to 91 
be applied during the formal validation step. 92 
From this quantitative information regarding the overall studied domain, a formal validation 93 
of a single set of working conditions could be considered. However, when considering the 94 
whole lifecycle of an analytical method, two major factors favor the continuous improvement 95 
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of the method. First, in-study results often highlight surprising discoveries (whether “good” or 96 
“bad”) about the procedure. Second, the product itself is generally subject to modification or 97 
alteration (i.e. minor modifications in the formulation of the product, testing of the product 98 
following a new type of stress test, specification changes, etc.). In these cases, a return to the 99 
procedure development stage should be encouraged, as facilitated by the implementation of a 100 
QbD approach. However, any time that the procedure changes, the need to partially or 101 
completely validate the adapted method should be considered [7]. Otherwise, a statistical 102 
demonstration of the method equivalence should be implemented. [19,20]. Taking this into 103 
account, the benefits of extending the QbD concept to the validation stage of the method 104 
would seem to be highly relevant. Indeed, this new strategy could allow the evaluation of the 105 
quantitative performance of the method within the qualitative DS. Within this high quality 106 
operational space, the quantitative robustness of the method would be evaluated for multiple 107 
operational conditions rather than for one single set of conditions, as usually occurs during the 108 
validation step. The evaluation of the proposed strategy forms the second part of the present 109 
study. For this purpose, a case study involving a method previously developed by the Quality-110 
by-Testing approach is selected. An optimization of this method was required for two reasons. 111 
First, an improvement of the separation and detection conditions was required in order to 112 
eliminate the on-column mutarotation phenomenon observed with amino sugars [21]. Second, 113 
a change in the biological matrix used (i.e. from dog plasma to human plasma) as well as a 114 





2 Experimental 119 
2.1 Chemicals and reagents 120 
Methanol (MeOH; HPLC gradient grade) was purchased from J.T. Baker (Deventer, the 121 
Netherlands). Water (ULC/MS grade), acetonitrile (ACN; HPLC supra-gradient grade) and 122 
formic acid (ULC/MS grade) were provided by Biosolve B.V. (Valkenswaard, the 123 
Netherlands). Ammonia solution (32%, extra pure), Ammonium acetate (AnalaR, Normapur) 124 
and Ammonium bicarbonate (Rectapur) were acquired from VWR International (Darmstadt, 125 
Germany). Ultrapure water was obtained from a Milli-Q Plus 185 water purification system 126 
from Millipore (Billerica, MA, USA). 127 
Chemicals (under confidential agreement) and reagents involved in the pre-validation study 128 
(i.e. Part I of the present study) were described in a previous study [14]. 129 
D-(+)-Glucosamine hydrochloride (99%+) and D-(+)-Galactosamine hydrochloride (99%+) 130 
were purchased from Sigma (St. Louis, MO, USA). D-(13C6)-glucosamine hydrochloride (99 131 
atom-% 13C), used as the internal standard, was provided by Omicron Biochemicals INC. 132 
(South Bend, IN, USA). 133 
Pooled human plasma of mixed gender origin (50% male donors / 50% female donors) was 134 
obtained from Sera Laboratories International Ltd. (Haywards Heath, United Kingdom). 135 
2.2 Sample preparation 136 
Within the framework of a new predictive approach applied to the pre-validation study phase 137 
of the method lifecycle (i.e. Part I of the present study), an a posteriori study was conducted 138 
based on previous research where the qualitative performance of this method had already been 139 
demonstrated [14]. Since the quantitative performance of the method can be affected only by 140 
the presence of unexpected compounds from aged placebo tablets (the pharmaceutical form 141 
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involved in the study), which interfere with both major impurities (P4NX99, P4FX98 and 142 
P4NX99-D, see [14] for details), samples were prepared using only these compounds. Stock 143 
solutions were prepared by dissolving an appropriate quantity of analytes in a mixture of 144 
formic acid 0.1% and MeOH in the proportions 80/20 (v/v). Two kinds of standard were then 145 
prepared by making suitable simultaneous dilutions of both stock solutions in the presence of 146 
the extracted placebo pharmaceutical form, in order to mimic real samples. The first standard 147 
contained a high concentration of P4NX99 and a low concentration of P4FX98 (100 ng mL-1 148 
and 50 ng mL-1 of injected concentrations, respectively), while the second standard was 149 
prepared with the opposite levels of concentration (25 ng mL-1 and 200 ng mL-1 of injected 150 
concentrations, respectively). These solutions were prepared independently and in triplicate. 151 
Another previous study [22] was also selected as a case study in order to illustrate the 152 
applicability of the QbD methodology throughout the method lifecycle and, in particular, 153 
during the validation phase (i.e. Part II of the present study). The screening part of the QbD 154 
development was conducted on a mixture of pure glucosamine and galactosamine chemicals 155 
at a concentration of 1000 ng mL-1 in order to ensure detection despite the use of a multiplex 156 
interface. During the subsequent phases of the QbD development, stock solutions were 157 
prepared and mixed together in plasma at appropriate concentration levels (see below). 158 
Prepared plasma samples were vortex-mixed for several seconds in order to achieve 159 
homogenization. A 100 μL aliquot of the plasma sample was loaded onto a Phree 160 
phospholipid removal cartridge acquired from Phenomenex (Torrance, CA, USA). 300 μL of 161 
a mixture of ACN with 1% formic acid were then added. Finally, vacuum was applied at 2-7 162 
inches Hg until the filtrate could be collected. 163 
2.3 Experiments 164 
Experiments were performed on two kinds of liquid chromatography (LC) coupled to mass 165 
spectrometer (MS) systems. The first system involved a High Performance Liquid 166 
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Chromatography (HPLC) system composed as follows: a Waters (Milford, MA, USA) sample 167 
manager 2777, a CTC Analytics AG (Zwingen, Switzerland) Stack Cooler DW with a CTC 168 
Analytics AG Peltier thermostat allowing samples to be cooled at 10 °C, four Waters binary 169 
HPLC pumps 1525μ and a Waters temperature control module controlling a column oven. 170 
This HPLC system was coupled to a Waters MicroMass single quadrupole mass spectrometer 171 
(Quattro, Ultima/ZQ) equipped, when necessary, with a MicroMass 4-way multiplex interface 172 
(MXI). The second system was composed of a Waters “I-Class” Ultra high Performance 173 
Liquid Chromatograph (UPLC) coupled with a Waters XEVO TQ-S tandem mass 174 
spectrometer (MS-MS). The HPLC/MS system was involved in the study of the new 175 
predictive approach for the pre-validation study (Part I of the present study) and during the 176 
screening phase of the QbD method development for the determination of glucosamine and 177 
galactosamine in human plasma (Part II of the present study). The UPLC/MS-MS system, on 178 
the other hand, was used during the optimization phase of Part II and during the quantitative 179 
Design Space determination study. 180 
The LC/MS conditions used during the experiments of the pre-validation study, described in 181 
the first part of this study, were fixed as defined under the QbD optimization study described 182 
in [14]. Four columns were simultaneously tested, using LC/MXI-MS equipment [14], 183 
throughout the screening study that took place during the second part of the present study. 184 
These were: 185 
- Grace Alltech (Columbia, MD, USA) Alltima HP HILIC 2.1x150 mm (3.0 μm) 186 
- Waters XBridge Amide 2.1x150 mm (3.5 μm) 187 
- Waters XBridge BEH HILIC 2.1x150 mm (3.5 μm) 188 
- ThermoFisher Scientific (Waltham, MA, USA) Syncronis HILIC 2.1x150 mm (5.0 189 
μm) 190 
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These columns were tested in order to select the best one for improving the chromatographic 191 
performance for a selective determination of glucosamine and galactosamine, in the shortest 192 
possible time, without causing the on-column motarotation of each epimer. Each column was 193 
also available in a UPLC geometry in order to conduct the optimization phase of the QbD 194 
development with the selected column using the UPLC/MS-MS equipment. The Liquid 195 
Chromatography and Mass Spectrometry conditions for the experiments, either fixed a priori 196 
based on scientific knowledge or investigated during the screening design as well as during 197 
the optimization phase and the quantitative Design Space determination, are described in 198 
Table 1. 199 
2.4 A predictive approach developed for the pre-validation study 200 
The responses obtained from the performance of the adapted DoE for P4FX98 and P4NX99 201 
were modeled in relation to the experimental factors of methanol, acetonitrile, and the buffer, 202 
as well as the concentrations of P4FX98 and of P4NX99, resulting in a multivariate 203 
calibration function: 204 
 205 
From this model, on a fine grid covering the experimental domain, responses for P4FX98 and 206 
P4NX99 were then simulated a large number of times (i.e. 10,000), for both the simulated 207 
calibration standards and the simulated validation standards. Different numbers of series (or 208 
runs) and replicates per series were tested to assess the predictive ability of the analytical 209 
procedure to be validated. Simulated results were then computed over the grid of the 210 
experimental domain for each combination of series and replicates per series. The probability 211 
of obtaining results within +/-15% of the nominal concentration was also computed. 212 
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2.5 Optimization study for the selective determination of 213 
glucosamine and galactosamine in human plasma 214 
The determination of the qualitative performance required for the selective determination of 215 
glucosamine and galactosamine (i.e. epimeric compounds) in human plasma was performed 216 
following the QbD approach. This approach, which has been well described in the scientific 217 
literature [23-25], was implemented, taking into account the separation of glucosamine and 218 
galactosamine, as well as some resulting extracted compounds from the human plasma 219 
matrix. The selected responses were the retention times of these compounds recorded in the 220 
Multiple Reaction Monitoring mode at a mass transition (m/z ratio) of 180/162. The mass 221 
transition (m/z) used for the internal standard was 186/168. In the present Analytical Quality-222 
by-Design study, the separation criterion (S) was considered as the most relevant Critical 223 
Quality Attribute (CQA). It should be noted that, from ICHQ8 reference document point of 224 
view, this definition of the CQA is slightly different. However, from an analytical point of 225 
view, all the characteristics involved in the optimization of the method can be considered as a 226 
CQA. This is the case of the separation criterion S in the present paper that must be within an 227 
appropriate limit to ensure the desired method quality. Indeed, without an appropriate 228 
separation any quantitative analysis could be performed for that quality purpose. A first 229 
screening DoE was performed for the selection of the column and the influent Critical Method 230 
Parameters (CMPs), allowing the determination of both amino sugars while avoiding the on-231 
column mutarotation phenomenon. Following this, a central composite design, with the ACN 232 
percentage in the mobile phase (X.ACN) and pH (pH) as factors, was conducted. Based on the 233 
current scientific knowledge of the influence of the temperature factor (T), this parameter was 234 
manually added to the optimization DoE, and was extended as far as possible within the 235 
capabilities of the equipment being used, leading to a custom central composite design with a 236 
total of 13 experimental conditions (n = 15). 237 
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The responses measured on each chromatogram were the retention times at the beginning, 238 
apex and end. The methodology, applied in order to calculate the DS based on the predictive 239 
responses and their associated prediction errors, was the same as that explained in previous 240 
papers [14,25,26]. In the present case, the following model was applied: 241 
 242 
Y = XB+E , (1) 243 
with ựn, the nth line of E , assumed to follow a multivariate Normal distribution,                   244 
          , n=1,...,N , with N  representing the number of experiments. X  is therefore the    245 
(N x F) centered and reduced design matrix and B  is the (F x M) matrix containing the F  246 
effects for each of the M = 3 x P responses. Ủ is the covariance matrix of the residuals. 247 
2.6 A Quality-by-Design approach for a quantitative Design Space 248 
determination 249 
The responses obtained from implementing the DoE for glucosamine and galactosamine were 250 
modeled in relation to the experimental factors pH and acetonitrile, as well as the 251 
concentrations of glucosamine and galactosamine, resulting in a multivariate calibration 252 
function: 253 
 254 
From this model, on a fine grid covering the experimental domain, responses for glucosamine 255 
and galactosamine were then simulated a large number of times (i.e. 10,000) for both the 256 
simulated calibration standards and the simulated validation standards. Simulated results were 257 
then computed over the grid of the experimental domain and the predictive probability of 258 
obtaining results within +/-15% of the nominal concentration was computed. 259 
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2.7 Software 260 
Coding was carried out with the R 2.15.1 software. The e.noval software v3.0 (Arlenda, 261 
Liège, Belgium) was used to compute the validation results of the analytical method and to 262 
obtain the accuracy profiles for the conventional approach to the validation step in order to 263 




3 Results and discussion 267 
Scientists traditionally consider all the steps of the method lifecycle as a series of stand-alone 268 
steps. Although the QbD approach is increasingly being applied nowadays, the pre-validation 269 
and validation studies are usually performed separately from this strategy. In this way, 270 
knowledge obtained during these particular steps of the lifecycle is only informative for one 271 
single set of work conditions. The QbD approach, on the other hand, allows a much broader 272 
outlook: working within an operational space while managing the risk. 273 
3.1 Part I: Pre-validation study during the QbD optimization step 274 
The optimization step of a method development considered by a QbD strategy allows the 275 
qualitative performance of the step to be determined within an operational space through the 276 
use of a DoE (i.e. the qualitative DS). If the optimization is successful, this step occurs 277 
immediately before the pre-validation study. Therefore, it seems conceivable that the DoE, 278 
performed during this particular step, could be elaborated further in order to simultaneously 279 
conduct both the optimization step and the pre-validation study phase. In this way, it would be 280 
possible to carry out an evaluation of the Design of Experiment to be implemented during the 281 
formal validation step. A recently developed stability-indicating method was selected to 282 
illustrate the use of this new approach as part of the pre-validation study. This method allows 283 
the selective determination of two major degradation products (i.e. P4NX99 and P4FX98, 284 
under confidential agreement) of the active principal ingredient of a commonly used medicine 285 
[14].  286 
In order to simultaneously perform the optimization step of the method as well as the pre-287 
validation study, the DoE used here needed to be adapted. In particular, each condition of the 288 
DoE was reproduced in triplicate, while at the same time, two different concentrations of 289 
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P4NX99 and P4FX98 were alternatively tested. These concentrations were selected to 290 
estimate the limit of quantification of the method (i.e. upper and lower). The DoE 291 
implemented during the optimization phase was then conducted once again taking into 292 
account these modifications. The DS obtained during the method development is illustrated in 293 
Fig. 1. This figure also presents the tested conditions of the DoE (red circles). The odd points 294 
were tested with a high concentration of P4NX99 (i.e. 100 ng mL-1) and a low concentration 295 
of P4FX98 (i.e. 50 ng mL-1) and inversely for the even points (25 ng mL-1 and 200 ng mL-1, 296 
respectively). This figure also shows a representative chromatogram for each condition of the 297 
DoE as well as a reminder both of the compounds investigated in each Selected Ion 298 
Monitoring chromatogram and of the Critical Quality Attributes selected. The joint predicted 299 
probabilities of meeting all of these CQAs with their acceptance limit (λ) for each specific 300 
point of the DoE as well as for the selected working point (i.e. the set of conditions selected 301 
for the formal validation [14], the blue spot) were also indicated. It should be noted that, in 302 
comparison with the usual optimization DoE, the adaptations did not increase the working 303 
time independently of the repetitions of the DoE points. 304 
From the 9 tested conditions, only 8 and 6 chromatograms were exploitable for P4FX98 and 305 
P4NX99, respectively. Indeed, chromatograms obtained at “P1” could not be used for either 306 
of the two compounds due to the fact that selectivity was made impossible by the presence of 307 
interfering compounds. For the same reason, data from conditions “P2” and “P3” were also 308 
rejected but only in the case of P4NX99. Moreover, a deconvolution process was required for 309 
some conditions, introducing additional uncertainty for these quantitative data. Based on the 310 
exploitable quantitative data, calibration and validation sets were simulated, as explained in 311 
the Experimental section above. In this way, the probability of each point of the DoE being 312 
within the acceptance limits, a priori fixed at +/- 15%, was calculated and the results are 313 
presented in Table 2. These experiments have also allowed simulating the probability 314 
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throughout the area defined by the DoE for each concentration. Unfortunately, with only 5 315 
usable conditions for P4NX99, this simulation was unsuccessful. Figure 2 shows the 316 
distribution of the probability being within the acceptance limits calculated with all the 317 
available quantitative data by concentration level for P4FX98. Fig. 2A shows the results 318 
obtained for a concentration level of 50 ng mL-1, while Fig. 2B presents the concentration 319 
level at 200 ng mL-1. Following this analysis, several Designs of Experiments, to be 320 
conducted during the validation step, were tested. The different designs evaluated were a 321 
combination of validation series and repetitions of validation standards during each series. A 322 
minimum of three validation series and a minimum of two repetitions for each series were 323 
considered since their combination led to the smallest Design of Experiments that would need 324 
to be implemented during a formal validation in order to attain sufficient statistical power. 325 
Ten thousand simulations were then computed for each combination in order to assess their 326 
probability of producing a successful validation. A validation was considered successful if the 327 
calculated tolerance interval at 95% was included within the acceptance limits fixed at +/- 328 
15% for each concentration level. Table 3 shows the probability of a successful validation 329 
according to the designs tested for each experimental condition of the optimization DoE. 330 
These results show a high probability of attaining a successful validation even in the case of a 331 
validation DoE considering three series and three repetitions per series throughout the 332 
optimization DoE. This probability approached 100% when a 4 by 4 DoE was considered. 333 
The line highlighted in bold in Table 3 presents the experimental condition of the 334 
optimization DoE that comes nearest to the validated working condition (i.e. the blue dot in 335 
Fig. 1). As demonstrated by the formal validation performed during the previous study [14], 336 
the tolerance interval at 95% was included within the acceptance limits fixed at +/- 15% for 337 
the concentration range between 50 ng mL-1 and 200 ng mL-1. In other words, the present 338 
study, performed a posteriori, predicts the success of the validation step as was actually 339 
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demonstrated during the formal validation. Quantified guarantees of achieving good levels of 340 
total error definitely represent a movement towards the next steps of the analytical method 341 
lifecycle, i.e. robust assessments and routines that can be used in the laboratory [27]. 342 
3.2 Part II: Validation of an operational space 343 
As a key concept of the method lifecycle, the Analytical Target Profile must firstly, be 344 
selected at an early stage of the QbD methodology and secondly, be exclusively directed by 345 
the final requirements of the user. In this context, the principal objective of a quantitative 346 
method is to quantify with confidence while assessing the risk. A qualitative DS obtained by 347 
applying a QbD strategy represents only a preliminary step in the implementation of an 348 
efficient quantitative method. Indeed, nowadays, the application of this methodology stops at 349 
this point. The quantitative performance of the method is then assessed for a single set of 350 
conditions within this operational space. The second part of the present study focuses on a 351 
similar application of the QbD strategy during the validation step. In order to illustrate this 352 
innovative methodology, a previously developed method, using the Quality-by-Testing 353 
approach, was selected [22]. This method needed to be optimized in order to allow the 354 
selective determination of glucosamine from galactosamine while avoiding the on-column 355 
mutarotation phenomenon observed with the initial method. The biological matrix considered 356 
was human plasma, while, simultaneously, the equipment being employed was a triple 357 
quadrupole mass detector. In a scenario such as this, where polar drug substances are 358 
analyzed at very low concentration levels in bioanalytical applications, hydrophilic interaction 359 
chromatography (HILIC) plays an important role due to its larger retention possibilities for 360 
this kind of compound, which occurs very widely in bioanalysis [26]. The use of large 361 
proportions of highly volatile organic components (e.g., acetonitrile, methanol, etc.) in the 362 
mobile phase provides excellent ionization efficiency with the commonly used MS sources 363 
such as electrospray ionization, and this leads to enhanced sensitivity [28,29]. 364 
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3.2.1 Qualitative DS: an operational space for the validation 365 
The screening part of this study has allowed selecting influential Critical Method Parameters 366 
(CMPs) as well as the column showing the greatest separation efficiency for glucosamine and 367 
galactosamine. This enabled to consider the following CMPs: ACN percentage (X.ACN varied 368 
between 80% and 90%), pH (pH varied between 5 and 10) and temperature (T varied between 369 
25 and 75 °C). UPLC rather than HPLC was used during the optimization DoE in order to 370 
enhance the selective capabilities and reduce the total run time of the method. Consequently, a 371 
geometric transfer was implemented for the selected column in order to move it towards the 372 
corresponding UPLC geometry. The selected column was a Waters Acquity UPLC BEH 373 
Amide 2.1x100 mm (1.7 μm). Enhanced separative capabilities are essential when 374 
considering the biological matrix during the optimization step. Indeed, a major concern 375 
regarding HILIC-MS(/MS) bioassays and even reversed-phase LC-MS(/MS) bioassays is the 376 
impact of the matrix effect (ME) [30-32]. As recommended by the FDA [33], the ME should 377 
be assessed during the development of the method. The specific methodology implemented 378 
during this study is detailed in the “Supplementary Data” document. 379 
Once the CMPs had been identified (i.e. X.ACN, pH and T) during the screening study, a 380 
custom central composite design (T was added manually) with a total of 13 experimental 381 
conditions (n = 15, central point tested in triplicate) was conducted. Human plasma spiked 382 
with glucosamine, galactosamine and the internal standard as well as non-spiked plasma (for 383 
the ME assessment, as explained in the “Supplementary Data” document) were tested. This 384 
experimental domain was carefully selected on the basis of the preliminary results obtained 385 
with pure chemicals in order to allow the separation of both the epimeric compounds at a 386 
transition of m/z: 180/162. The concentration of the internal standard was fixed at 250 ng mL-1 387 
for all the solutions. Finally, as is now widely discussed in the scientific literature [23-25], a 388 
 19 
qualitative DS was computed using Monte-Carlo simulations from the prediction errors of a 389 
set of CQAs for which the acceptance limits (λ) were fixed, as described below: 390 
- Separation between glucosamine, galactosamine and endogenous plasma compounds 391 
eluted just before epimeric compounds > 0.2 min. 392 
- Total run time < 30 min. 393 
A three-dimensional (X.ACN, pH, T) probability surface was then obtained. Three 394 
representative slices of this multi-dimensional surface are presented in Fig. 3. The two-395 
dimensional representations were obtained by fixing one parameter at its optimal value in the 396 
case of Fig. 3A and Fig. 3B, while T was fixed at 50 °C in the case of Fig. 3C, since this was 397 
the selected working temperature for the validation of the operational space. Fig. 3A, where 398 
the fixed parameter was X.ACN at 88.5%, shows that the interaction pH – T was barely 399 
significant. However, a DS with a quality level (π) of more than 0.81 was defined for a pH 400 
ranging from 5.2 to 6.4 and a T ranging from 35 °C to 75 °C. The slice where the pH 401 
parameter was fixed at 5.75 is presented in Fig. 3B. At 50 °C and above, the level of quality 402 
obtained when considering all the constraints (i.e. the CQAs) was found to be acceptable and 403 
relatively constant for the parameter X.ACN ranging from 83% to 89%. This finding is 404 
confirmed by Fig. 3C, which presents the computed probability surface at a fixed temperature 405 
of 50 °C, in particular for the range of pH between 5 and 6.8. Within this area, dark lines 406 
highlight two DS, with a π of 0.825. These DS represent the sets of conditions where the 407 
chromatographic performance, with regard to the separation of glucosamine, galactosamine 408 
and endogenous plasma compounds within a maximum run time of 30 minutes, presented a 409 
very acceptable level of quality. 410 
3.2.2 Strategy for the validation of an operational space 411 
Once the qualitative DS has been obtained, the next step of the method lifecycle is the 412 
validation of the method. As with the conventional approach to the validation, a unique set of 413 
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conditions within the qualitative DS is chosen. A validation DoE is then applied to the 414 
selected working conditions, considering an approach using accuracy profiles based on 415 
statistical tolerance intervals. Nowadays, this approach is fully approved by the authorities 416 
[18], as well as being widely discussed and applied by scientists [34-35]. Within the 417 
qualitative DS centered around the parameter X.ACN at 86% in Fig. 3C, the working 418 
conditions defined by the red dot (i.e. X.ACN = 86%, pH = 6, T = 50 °C) could have been 419 
appropriate and therefore suitable to be subjected to a formal validation. However, this 420 
conventional approach only allows the assessment of the quantitative performance of the 421 
method for the selected working conditions, which represents a break from the QbD process. 422 
Indeed, the qualitative performance of the method is evaluated throughout a defined domain, 423 
but the quantitative performance is only assessed for one single set of conditions. The 424 
qualitative DS guarantees an area of robustness for the studied CMPs in terms of the selected 425 
CQAs. Consequently, the analyst is able to find alternative working conditions, where the 426 
qualitative performance is already demonstrated. This allows him/her to be able to respond to 427 
an unexpected or a scheduled change in the method that originates from a separation issue. 428 
Nevertheless, this learning process is only applicable for the qualitative part of the method, 429 
not for its quantitative performance. How can the quantitative performance of the newly 430 
selected working conditions be assessed? Without any further information, the analyst could 431 
be placed in in the position of selecting, within the operational space, a working condition 432 
with a poor probability of validation success. In order to provide a remedy for this scenario, 433 
an innovative validation approach, based on the QbD concept, was applied to the case study 434 
addressed in this section. 435 
Within the probability surface presented in Fig. 3C, a qualitative DS was selected that was as 436 
large as possible, and with a minimum quality level (π) of 0.5. This is outlined in the figure 437 
by the blue lines. Both the blue dots and the red dot represent the experimental conditions 438 
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tested during the validation DoE for this operational space. The red dot represents the central 439 
condition of this custom DoE but also the condition selected as a reference to compare with a 440 
conventional approach to the validation step (i.e. a validation of a unique set of conditions 441 
within the operational space). The parameter T was fixed at 50 °C since the separative 442 
performance compared to the optimal temperature (i.e. 62.5 °C) was similar and the lower 443 
temperature exerted less of a strain on the equipment. The design of experiments for the 444 
validation was developed for a period of 3 series throughout the operational space, as can be 445 
seen in Fig. 4. For each series, a minimum of 2 repetitions of the calibration standard for each 446 
concentration level was tested. In the meantime, a minimum of 5 repetitions of the validation 447 
standard for each concentration level was also tested. Three repetitions were always 448 
performed in the case of the validation standards for the reference points, as flagged with the 449 
red color in Fig. 4. Three concentration levels were tested for glucosamine and galactosamine, 450 
covering a range from 25 ng mL-1 to 500 ng mL-1 and from 200 ng mL-1 to 1000 ng mL-1 451 
(injected concentrations) in all the standards, respectively. Each sample was spiked with the 452 
internal standard in order to obtain a concentration of 500 ng mL-1 (injected concentration). 453 
3.2.3 Validation results  454 
Computation of data gathered via this validation DoE throughout the operational space was 455 
performed as explained in the Experimental section above. A probability surface was 456 
calculated for each concentration level of glucosamine and galactosamine, and this is 457 
presented in Fig. 5A and Fig. 5B, respectively. Each probability surface represents the 458 
probability that each future result, for the concentration level tested and throughout the 459 
operational space, will be between +/- 15% of the true value. This predictive methodology is 460 
similar to the one used during the conventional approach to the validation for the “Ữ-461 
expectation tolerance interval” and allows the assessment of a key feature of the validation 462 
study within an operational space: the uncertainty regarding the performance of the method. 463 
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As can be seen in Fig. 5A, probability surfaces obtained for the validation of the 464 
determination of glucosamine in human plasma were extremely homogenous throughout the 465 
operational space and for the entire considered dosing range. The probability of being within 466 
+/- 15% of the true value was always higher than 97%, whatever the concentration level. 467 
Based on this evaluation, taking into account all the validation results with their associated 468 
uncertainty, the quantitative performance of the method was guaranteed across the operational 469 
space for glucosamine. The validation data gathered for galactosamine on the other hand led 470 
to a distinctive situation. In this case, the computed probability surfaces, also taking into 471 
account all the validation results with their associated uncertainty, showed a probability of 472 
being within +/- 15% of the true value ranging between 68% and 72% for concentration levels 473 
of 500 ng mL-1 and 1000 ng mL-1. This probability fell between 45% and 72% for the lower 474 
concentration level (i.e. 200 ng mL-1). From the perspective of a formal validation, these 475 
results could not be considered as acceptable. However, these probability surfaces led to the 476 
discovery of some very useful information. As can be seen in Fig. 5B, a high percentage of 477 
ACN and pH resulted in a greater chance of achieving a successful validation. With this 478 
information, it would be possible to influence positively the selection of different working 479 
conditions, sometimes necessary during the life cycle of the method (i.e. continuous 480 
improvement process). In addition to computing these probability surfaces, a probability 481 
profile could be computed from those first results for a specific set of working conditions 482 
within the operational space. These probability profiles could then be compared to the risk (α) 483 
profiles obtained during a formal validation (i.e. the risk α = 1 – the probability of being 484 
within +/- 15% of the true value). Furthermore, accuracy profiles could also be computed 485 
from these probability surfaces for a specific set of working conditions within the operational 486 
space. 487 
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3.2.4 Comparison with a conventional approach to the validation step 488 
The DoE of this innovative strategy was wisely elaborated. Indeed, experiments on the central 489 
working conditions were repeated as for a formal validation, testing 3 repetitions of the 490 
validation standards over 3 working days (see Fig. 4). In this context, these experiments could 491 
be independently computed in order to obtain results in the same way as from a formal 492 
validation of the method. As suggested in the section above, an accuracy profile could be 493 
calculated for each working condition within the operational space and for each analyte. 494 
These profiles could thus be compared to those obtained from the formal validation of the 495 
central point, as can be seen in Fig. 6A and Fig. 6B for glucosamine and galactosamine, 496 
respectively. As can be seen on the right hand side of Fig. 6A, the formal validation of the 497 
selected working conditions (i.e. the central point of the validation Design of Experiments) 498 
was successful for glucosamine. The quantitative performance for this molecule throughout 499 
the operational space was very good and homogenous, as highlighted in Fig. 5A. 500 
Consequently, very accurate predictions for each set of working conditions within the 501 
operational space were obtained when considering all the validation results with their 502 
associated uncertainty. Unlike the glucosamine results, those obtained for galactosamine were 503 
less favorable. Indeed, the quantitative performance throughout the operational space was 504 
found to be less homogeneous. However, as can be seen in Fig. 6B, analysis of the validation 505 
results for the central condition of the validation DoE led to a successful validation when 506 
considering a formal validation process. As the strategy developed for the validation of the 507 
operational space considered the uncertainty throughout that entire operational space, the 508 
predictive validation results were less optimistic than when only a single set of working 509 
conditions was considered. These poorer predictive results may thus have been the result of a 510 
lack of statistical power. As with a formal validation process, an additional validation series 511 
(i.e. an additional working day) could be considered here. The validation DoE presented in 512 
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Fig. 4 would thus need to be adapted in order that these additional experiments cover the 513 
operational space. Computation of the results of the validation DoE has also allowed to 514 
calculate the probability profiles for any working conditions within the operational space, as 515 
explained in the previous section. In the case of glucosamine, the risk (α) throughout the 516 
dosing range for the central experimental condition of the validation DoE was calculated and 517 
was shown to vary between 0.1% and 0.4%. The result regarding the same parameter obtained 518 
via the formal validation varied between 0.1% and 0.5%. This comparison demonstrates the 519 
high quality of prediction across the entire operational space in the case of glucosamine. 520 
Moreover, the linearity of the method throughout the operational space was calculated from 521 
all the results of the validation DoE and compared to the results obtained via the formal 522 
validation. In the case of glucosamine, the slope, the intercept and the coefficient of 523 
determination (R2) were equal to 1.00, 0.26 and 0.99, respectively. In the case of the formal 524 
validation, the calculations of these results were equal to 1.00, -0.05 and 0.99, respectively. 525 
These results demonstrate once more the high quality of the prediction obtained by this 526 
validation Design of Experiment. This validation of the operational space was performed over 527 
three working days as for a formal validation, confirming the quantitative performance of the 528 
method across an area rather than for a single set of conditions during the same time period as 529 




4 Conclusion 533 
Defining the objectives of the method using an Analytical Target Profile (ATP) should be the 534 
first step of the QbD methodology. In the case of the development of a quantitative method, 535 
this ATP should also be focused on the quantitative performance of the method. By 536 
integrating the pre-validation study alongside the QbD optimization phase, some parameters 537 
of the validation can be evaluated. As described in the first part of this study, the Design of 538 
Experiments for use during a formal validation can be developed simultaneously with the 539 
selection of the qualitative Design Space, without increasing the working time usually 540 
dedicated to this step of the method lifecycle. Following a similar approach, an estimation of 541 
the calibration model, the accuracy, and the limits of detection/quantification may also be 542 
considered during this step. Consequently, the methodology to be implemented would require 543 
further improvement. In particular, repetitions considered at each experimental point would 544 
need to be made with more than one concentration level in order to improve the quality of the 545 
prediction. 546 
As specified in the latest USP [18] and FDA [36] documents, the validation step of the 547 
method lifecycle must not be an isolated activity but should be part of the continuous 548 
improvement of the method. The routine use of the method allows the continuous acquisition 549 
of information via quality control samples, for instance. However, without a deep 550 
understanding of the method (i.e. qualitative and quantitative knowledge), it is rather difficult 551 
to take advantage of the information gained. For example, with the case study presented here 552 
for glucosamine determination, and even for galactosamine, the quantitative and qualitative 553 
information obtained, would allow the analyst to consider selecting other working conditions 554 
within the operational space with great confidence. Indeed, using this strategy, it would thus 555 
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be possible to evaluate the quantitative performance of the method before the selection of 556 
different working conditions. This would allow a corrective action to be implemented or a 557 
preventive action to be initiated following, for instance, a problem encountered during the 558 
routine use of the method. This methodology is not restricted to overcoming routine issues. It 559 
could also be employed when a change of the applicability of the method needs to be 560 
considered, for instance, a change in the biological matrix (gender, species, etc.). It is for this 561 
reason that this innovative strategy combines both a learning process and a thorough 562 
assessment of the risk. However, even though this did not happen with the presented case 563 
study, this innovative approach could lead to the use of a validation protocol that is more 564 
expensive in terms of analytical time. This concern would need to be addressed with further 565 
development of the strategy. Nonetheless, from our point of view, this potential additional 566 
analytical cost should be set against the benefits provided by this approach during the whole 567 
analytical lifecycle. 568 
 569 
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List of figures 666 
Figure 1: Qualitative DS obtained during the method development. The red circles represent 667 
the tested conditions with their representative chromatogram and estimated probability. Peaks 668 
obtained in each chromatogram for both channels are labeled from “a” to “f”. A summary of 669 
the CQAs selected with their acceptance limit (λ) for obtaining the qualitative DS are also 670 
specified. The blue spot represents the set of working conditions selected for the formal 671 
validation of the method (see [14]). 672 
 673 
Figure 2: Simulation of the distribution of the probability of being within the acceptance 674 
limits of +/- 15% for P4FX98. (A) Concentration level at 50 ng mL-1. (B) Concentration level 675 
at 200 ng mL-1. 676 
 677 
Figure 3: Two-dimensional qualitative probability surfaces (i.e. P(CQAs > λ)) with their DS 678 
defined by a dark line. (A) X.ACN was fixed at 88.5%, pH varied between 5 and 10 and T 679 
varied between 25 °C and 75 °C. (B) pH was fixed at 5.75, X.ACN varied between 80% and 680 
90% and T varied between 25 °C and 75 °C. (C) T was fixed at 50 °C, pH varied between 5 681 
and 10 and X.ACN varied between 80% and 90%. The area surrounded by blue dots and blue 682 
lines represents the qualitative DS selected as the operational space. The red dot corresponds 683 
to the reference point selected for the formal validation. 684 
 685 
Figure 4: Design of Experiments for the validation of the operational space. The flags over 686 
the experimental conditions represent the number of repetitions using the color coding 687 
indicated on the top right hand side of the figure. 688 
 689 
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Figure 5: Probability of the surface being within +/- 15% of the true value by concentration 690 
level for (A) glucosamine and (B) galactosamine 691 
 692 
Figure 6: Accuracy profile of the validation of the working conditions of the reference point 693 
obtained for (A) glucosamine and (B) galactosamine. On the left hand side of the figure, 694 
accuracy profiles are obtained from the validation DoE. The accuracy profiles presented on 695 
the right hand side of the figure, were obtained by performing a formal validation of the 696 
selected set of conditions. The plain red lines represent the relative bias, the dashed lines 697 
represent the 95% Ữ-expectation tolerance limits and the dotted curves represent the 698 








Table 1: LC and MS conditions, a priori fixed or investigated, during the screening design as well as during the optimization phase and quantitative Design Space 
determination 
 Screening Design 
(HPLC/MS) 
Optimization design Quantitative DS determination 
 (UPLC/MS-MS) (UPLC/MS-MS) 
Type of DoE conducted Fractional Factorial Design Central Composite Design Custom Central Composite Design 
ACN percentage (%) 
(binary mixture with buffer) 65 – 90 80 – 90 83.5 – 88.5 
Buffer concentration (mM) 10 – 50 150 150 
pH of mobile phase 3 – 7.5 5 – 10 5.25 – 6.75 
Column temperature (°C) 25 25 – 75 50 
GluN concentration (ng mL-1) 1000 50 – 500 25 – 500 
GalN concentration (ng mL-1) 2000 200 – 1000 200 – 1000 
GluN-13C6 concentration (ng mL-1) NA 250 500 
Flow rate (μL min-1) 250 300 300 
Injection volume (μL) 10 10 10 
MS or MS-MS mode GluN/GalN (m/z) 180 180.2 à 162.2 
MS or MS-MS mode GluN-13C6 (m/z) NA 186.2 à 168.2 
MS source and mode ESI+ 
Cone temperature (°C) 100 150 
Capillary temperature (°C) 400 500 
Nebulizer gas (L h-1) 100 150 
Desolvation gas (L h-1) 500 1000 
Cone voltage (V) 18 25 
Capillary voltage (kV) 3.00 3.50 
Source offset (V) NA 60.0 
Collision gas flow rate (mL min-1) NA 0.25 
Nebulizer gas flow (bar) NA 7.00 
MS-MS mode collision energy (eV) NA 7.00 
Dwell time for GluN and GalN (ms) 125 250 
Dwell time for GluN-13C6 (ms) NA 30 
NA: Not Applicable    
 
Table 2: Probability of obtaining results within the acceptance limits of +/- 15% for each experimental point of the DoE 
Experimental 
point of the DoE MeOH ACN Buffer 
P4FX98 
concentration Probability 
P2 0.171 0.069 0.76 200.6 0.6927 
P3 0.0752 0.0752 0.8496 50.15 0.2001 
P4 0.162925 0.033075 0.804 200.6 0.5512 
P5 0.1995 0.0405 0.76 50.15 0.9458 
P6 0.24 0 0.76 200.6 0.4996 
P7 0.10716 0.04324 0.8496 50.15 0.2486 
P8 0.1504 0 0.8496 200.6 0.4707 
P9 0.1864 0 0.8136 50.15 0.1651 
 
Table 3: Probability (%) of attaining a successful validation according to the tested designs (day x repetition) for the acceptance limits of +/- 15% and a probability of 95% of 
attaining future results within these limits 
    Probability of validation success (%) 
Experimental point 
of the DoE MeOH ACN Buffer 3x3 4x2 4x3 4x4 
P2 0.171 0.069 0.76 98.9 98.9 99.6 100.0 
P3 0.0752 0.0752 0.8496 99.5 98.9 99.8 99.9 
P4 0.162925 0.033075 0.804 99.5 99.1 100.0 100.0 
P5 0.1995 0.0405 0.76 99.3 98.2 99.9 100.0 
P6 0.24 0 0.76 99.5 98.5 99.8 99.9 
P7 0.10716 0.04324 0.8496 99.5 99.3 99.7 99.9 
P8 0.1504 0 0.8496 99.4 99.2 99.7 99.9 
P9 0.1864 0 0.8136 99.1 98.8 99.7 99.9 
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Matrix effect assessment 20 
Enhanced separative capabilities were essential when considering the biological matrix during 21 
the optimization step. Indeed, A major concern about HILIC/MS(-MS) bioassays or even 22 
reversed-phase LC/MS(-MS) bioassays is the impact of the matrix effect (ME). The ME 23 
refers to the ionization suppression or enhancement caused by unobserved substances co-24 
eluted from biological matrix. This kind of co-elution competition takes place between 25 
compounds during the ionization process, and especially when considering ESI mode [25-27]. 26 
Therefore, minimizing this phenomenon is crucial. In the case of this study, a generic protocol 27 
combining acidified organic protein precipitation (i.e. ACN with 1% formic acid) and specific 28 
extraction of phospholipids was conducted using Phree Phospholipid Removal Plates from 29 
Phenomenex by the mean of a vacuum manifold. However, as recommended by FDA [28], 30 
the lack of ME has to be assessing during the development of the method. This can be done 31 
by the monitoring of the variability of the MS response for the analyte using a post-column 32 
infusion scheme during the analysis of an extracted blank matrix sample. This methodology 33 
allows identifying the chromatographic region where compounds responsible of the ME are 34 
eluted for the tested experimental condition. As the ME could be due to many endogenous 35 
compounds, it is difficult to manage this response such as a unique compound. Consequently, 36 
this methodology only leads to a categorical response: the lack or not of a matrix effect at the 37 
retention time of target analyte. This king of response is difficult to model throughout the 38 
entire experimental space. Therefore, a more specific methodology was envisaged in order to 39 
assess this problematic. In the case of HILIC method, ME is largely encountered due to a co-40 
elution between early-eluted analytes and endogenous phospholipids or formulation vehicles 41 
[27]. Other endogenous compounds typically responsible of the ME in reversed-phase mode 42 
are potentially present but are directly eluted in HILIC mode. In this framework, precursor ion 43 
scans with the product ion of m/z: 184 (i.e. the specific daughter ion from the hydrophilic 44 
 3 
head of the phospholipids) were performed with the scan range from 490 to 890 m/z for each 45 
experimental condition with none spiked plasma. A combination of all recorded spectra 46 
during the run time for each experimental condition were performed in order to identify 47 
potential phospholipids remaining after plasma preparation. Specific transition of identified 48 
phospholipids (i.e. m/z: 496-184, 760-184 and 786-184, principally) were then extracted from 49 
each chromatogram in order to compare the retention time of this particular phospholipids 50 
with the retention time of glucosamine and galactosamine obtained from the analysis of 51 
spiked plasmas. This methodology allowed modeling the chromatographic behavior of 52 
remaining phospholipids in order to introduce a separation criteria of remaining 53 
phospholipids, glucosamine and galactosamine as a CQA if necessary (i.e. if remaining 54 
phospholipids were eluted within the retention windows of glucosamine or galactosamine). 55 
Thanks this methodology, the separative DS could manage the ME throughout the envisaged 56 
experimental domain as requested by FDA recommendations. In the case of the present study, 57 
no remaining phospholipids were found to elute within the retention time windows of 58 
glucosamine or galactosamine for any experimental condition. 59 
 60 
